Akero Therapeutics, Inc.
AKRO
$48.43
$0.400.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.14M | 39.94M | 37.93M | 37.68M | 36.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 321.48M | 306.35M | 285.42M | 269.27M | 234.18M |
| Operating Income | -321.48M | -306.35M | -285.42M | -269.27M | -234.18M |
| Income Before Tax | -283.96M | -269.44M | -252.06M | -237.22M | -204.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283.96 | -269.44 | -252.06 | -237.22 | -204.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283.96M | -269.44M | -252.06M | -237.22M | -204.18M |
| EBIT | -321.48M | -306.35M | -285.42M | -269.27M | -234.18M |
| EBITDA | -321.46M | -306.33M | -285.41M | -269.27M | -234.17M |
| EPS Basic | -3.80 | -3.75 | -3.75 | -3.75 | -3.41 |
| Normalized Basic EPS | -2.29 | -2.25 | -2.25 | -2.28 | -2.07 |
| EPS Diluted | -3.80 | -3.75 | -3.75 | -3.75 | -3.41 |
| Normalized Diluted EPS | -2.29 | -2.25 | -2.25 | -2.28 | -2.07 |
| Average Basic Shares Outstanding | 300.39M | 287.83M | 268.48M | 253.63M | 239.80M |
| Average Diluted Shares Outstanding | 300.39M | 287.83M | 268.48M | 253.63M | 239.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |